Chemours price target raised to $28 from $21 at UBS

UBS analyst Joshua Spector raised the firm’s price target on Chemours to $28 from $21 and keeps a Neutral rating on the shares. The company’s Q4 earnings and 10-K filing suggest that its main issues around accounting and management are mostly resolved, though the lower guidance for Q1 adds some more questions about earnings over the next year, the analyst tells investors in a research note. Both TiO2 and the Thermal & Specialized Solutions segment earnings will move higher into 2025, but the firm remains neutral on the stock pending more visibility on margins and volumes, the firm added.